Infliximab maintenance therapy for fistulizing Crohn's disease.

By Bruce E. Sands, F. Anderson, C. Bernstein, W. Chey, B. Feagan, R. Fedorak, M. Kamm, J. Korzenik, B. Lashner, J. Onken and 8 more. New England Journal of Medicine, 2004

2,194 citations recorded by the source corpus.

Subfields: Epidemiology, Genetics, Surgery

View Paper: https://www.semanticscholar.org/paper/40f1a07ff6510294163b5c55b8aea70ffc5b0662

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. W. Sandborn
2. J. Colombel
3. L. Peyrin-Biroulet
4. S. Hanauer
5. Joel T. Dudley
6. Atul J. Butte
7. Annie P. Chiang
8. F. Balkwill

In Genetics

1. W. Sandborn
2. J. Colombel
3. L. Peyrin-Biroulet
4. S. Hanauer
5. G. Lichtenstein
6. B. Feagan
7. E. Loftus
8. P. Rutgeerts

In Surgery

1. J. Bradley
2. S. Hanauer

Citations in the corpus

• Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease (2011, background): “Chronic use of corticosteroids or systemic anti-inflammatory drugs (for example, 6-mercaptopurine) typically used to treat IBD is associated with severe side effects, and more targeted therapies such as anti-TNFa (tumor necrosis factor–a) drugs incur high costs and elicit a therapeutic response in o”
• Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management (2016, background): “Regarding the time frame, there is agreements in clinical trials that PNR to anti-TNF drugs should not be assessed prior to 14, 12, or 8 weeks following initial infusions, respectively, with infliximab, adalimumab (ADA), and certolizumab.(3,4)”
• Infliximab for induction and maintenance therapy for ulcerative colitis. (2005, background): “[15-18] However, the few small studies of infliximab in patients with active ulcerative colitis have yielded conflicting results.”